Allogene Therapeutics (ALLO) Rating Reiterated by William Blair

Share on StockTwits

Allogene Therapeutics (NASDAQ:ALLO)‘s stock had its “buy” rating restated by stock analysts at William Blair in a report issued on Monday, AnalystRatings.com reports.

ALLO has been the subject of several other research reports. Cowen reiterated a “buy” rating on shares of Allogene Therapeutics in a report on Friday, March 8th. Piper Jaffray Companies initiated coverage on shares of Allogene Therapeutics in a report on Friday, March 29th. They set an “overweight” rating and a $50.00 price target for the company. Zacks Investment Research cut shares of Allogene Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, April 8th. JPMorgan Chase & Co. reiterated a “hold” rating and set a $29.00 price target on shares of Allogene Therapeutics in a report on Monday, March 11th. Finally, Raymond James initiated coverage on shares of Allogene Therapeutics in a report on Thursday, March 14th. They set an “outperform” rating and a $40.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Allogene Therapeutics has a consensus rating of “Buy” and an average target price of $36.83.

Shares of ALLO stock traded down $0.41 during trading on Monday, reaching $25.91. The company’s stock had a trading volume of 4,090 shares, compared to its average volume of 517,968. Allogene Therapeutics has a 1-year low of $21.67 and a 1-year high of $35.55. The stock has a market capitalization of $3.19 billion and a P/E ratio of -3.93.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Friday, March 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). Equities analysts forecast that Allogene Therapeutics will post -2.13 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at $156,000. Rhumbline Advisers acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at $829,000. Creative Planning acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at $544,000. Shikiar Asset Management Inc. acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at $1,056,000. Finally, TD Asset Management Inc. acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at $674,000. Institutional investors own 51.60% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.

Further Reading: Do Tariffs Work?

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Observer Price Tops $0.0018
Observer Price Tops $0.0018
$0.02 Earnings Per Share Expected for First Solar, Inc.  This Quarter
$0.02 Earnings Per Share Expected for First Solar, Inc. This Quarter
Kenadyr Mining  Reaches New 1-Year Low at $0.06
Kenadyr Mining Reaches New 1-Year Low at $0.06
PlayCoin [ERC20]   Trading 30.1% Lower  Over Last 7 Days
PlayCoin [ERC20] Trading 30.1% Lower Over Last 7 Days
$5.30 Billion in Sales Expected for Mcdonald’s Corp  This Quarter
$5.30 Billion in Sales Expected for Mcdonald’s Corp This Quarter
Rizal Resources  Sets New 1-Year Low at $0.01
Rizal Resources Sets New 1-Year Low at $0.01


© 2006-2019 Ticker Report